Section 5 of 5
Conclusion
Felix Lindberg, Alicia Uijl, Lina Benson, Valeria Valente, Andrew J S Coats, Michael Böhm, Marco Metra, Stefano Masi, Lars H Lund, Giuseppe M C Rosano, and Gianluigi Savarese · about 1 minutes
As of 2023, use of quadruple HFrEF therapy reached ∼60% and was mostly limited by the lower adoption of MRA (∼73%). Patient adherence to HFrEF foundational therapies was high and appeared associated with better prognosis. These data suggest that improving the uptake of quadruple HFrEF pharmacotherapy is achievable in specific healthcare settings, although suboptimal dosing and frequent discontinuations remain important areas of further implementation, suggesting a need for sustained monitoring for preventable discontinuations. Efforts targeting physician-level implementation, healthcare system-level, and patient-level adherence and persistence are key to transport the effect in trials to the real-world HFrEF population.